BIO was as busy as ever in Boston this year. With more to come soon, here are a few initial thoughts on three events I ...

New IRS requirements for R&D tax credits are coming into effect for tax year 2025. Life sciences companies should prepare for ...

Proper legal structuring is essential when it comes to transferring Chinese biotech intellectual property and clinical assets ...

Experts at PA Consulting offer case studies and advice for using generative AI to improve biopharma manufacturing, mitigate ...

The European Union (EU) is actively courting biotech for economic growth and has launched several initiatives to attract ...

After decades of racing to the bottom on pricing, a revolution is coming to the U.S. generics market, writes Yaral Pharma CEO ...

Advocacy for alternatives to animal testing in clinical research is pushing the industry away from animal-based endotoxin ...

Recently, there has been heightened focus on dual brand approaches in which the same molecule is approved for multiple indications and packaged, priced, and distributed under different brand names.

With the enthusiasm surrounding innovative product types and therapeutic approaches — and the corresponding rush to bring these new products to market — company leaders should double down on internal ...

For people living with schizophrenia, the current drug treatment landscape is filled with cracks, crevices, and canyons that prevent a majority of patients from reaching anything close to a normal ...

Good mental health (MH) and psychological well-being are fundamental human concerns in determining human happiness and flourishing, both in private and working life. One of the most comprehensive and ...

It was the summer of 2007 when Chris Anzalone, Ph.D., got a call from Arrowhead Research Company. At the time, Anzalone was working as CEO of the Bennet Group, a private equity firm in Washington, D.C ...